Patients

OncoSec exists for you, the patient.

We believe that knowledge holds the key to developing
responsive, quality treatments.
OncoSec encourages patients and care partners to
research and explore educational resources to better
understand cancer and the organizations that are
committed to offering treatment and support.


Clinical Trials

Currently, we have two clinical trials evaluating the safety and durability of TAVO in combination with pembrolizumab to treat patients who who have progressed or are progressing on an approved checkpoint inhibitor (like pembrolizumab or nivolumab).

Scientific Publications

Our clinical trial findings on TAVO are significant, but they are just the beginning!


Testimonial – A Patient’s Perspective

Immunotherapy is changing the way we perceive and treat cancer. Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the power of the immune system to fight disease. We are witnessing the emergence of a new vision within the cancer treatment landscape – one that is having an immediate and powerful impact on cancer patients everywhere.

Melinda Welsh who documented her diagnosis and treatment of squamous cell carcinoma of the head and neck in the Los Angeles Times. The first article discusses her diagnosis and the possibility of enrolling in a clinical trial to test OncoSec’s investigational therapy, TAVO. The second article describes her treatment with TAVO and the results that she experienced. Her story is a poignant reminder of why OncoSec is focused on cancer immunotherapy and developing new treatments for patients.

Los Angeles Times – ‘I have terminal cancer. And I’m dying in a yearish.’
Los Angeles Times – I have terminal cancer and I know my friends want to ask, ‘Aren’t you dead yet?’

OncoSec’s product candidates are investigational and have not been approved by the FDA. The results described in these testimonials may not be representative of the patient experience as the product candidates remain investigational.